{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:42:02Z","timestamp":1794321722035,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.drugalcdep.2025.112840","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T06:22:32Z","timestamp":1755238952000},"page":"112840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3537-8289","authenticated-orcid":false,"given":"Bernardo","family":"de Faria Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7836-7497","authenticated-orcid":false,"given":"Gabriel","family":"Andr\u00e9 Pedral Diniz Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Andr\u00e9 Pedral Diniz Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8679-382X","authenticated-orcid":false,"given":"Igor Boechat","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nath\u00e1lia Veloso","family":"Lana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7824-2152","authenticated-orcid":false,"given":"Guilherme Grossi Lopes","family":"Can\u00e7ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112840_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40265-025-02177-x","article-title":"Association of Glucagon-Like Peptide-1 receptor agonist with progression to liver cirrhosis and Alcohol-Related admissions in patients with alcohol use disorder and diabetes: a retrospective cohort study","volume":"85","author":"Al-Moussally","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib3","first-page":"656","article-title":"FDA approves tirzepatide as first drug for obstructive sleep apnea","volume":"333","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in Male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib10","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3350\/cmh.2024.0835","article-title":"Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021","volume":"31","author":"Danpanichkul","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2468-1253(24)00380-7","article-title":"Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective","volume":"10","author":"D\u00edaz","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring Male vervet monkeys","volume":"242","author":"Fink-Jensen","year":"2025","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies","volume":"14","author":"Jerlhag","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70004","article-title":"Effects of GLP-1 receptor agonists in alcohol use disorder","volume":"136","author":"Klausen","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/apt.70007","article-title":"Impact of GLP-1 receptor agonists on Alcohol-Related liver disease development and progression in alcohol use disorder","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib22","first-page":"1831","article-title":"Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease","volume":"18","author":"Long","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib24","series-title":"Treatment of alcohol use disorder","author":"Mar","year":"2023"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib25","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","article-title":"MetALD: does it require a different therapeutic option?","volume":"80","author":"Marek","year":"2024","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib26","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib27","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and Meta-Analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib28","first-page":"e2","article-title":"Pharmacologic interventions for alcohol use disorder","volume":"38","author":"Menge","year":"2025","journal-title":"JAAPA Off. J. Am. Acad. Physician Assist"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/alcalc\/agac013","article-title":"Alcohol consumption: medical implications, the liver and beyond","volume":"57","author":"Meza","year":"2022","journal-title":"Alcohol. Alcohol. Oxf. Oxfs."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib33","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib36","article-title":"Impact of GLP-1RA on the risk of adverse liver outcomes among patients with Alcohol-Associated liver disease and type 2 diabetes","volume":"45","author":"Rashid","year":"2025","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1037\/1082-989X.6.4.387","article-title":"Effects of study duration, frequency of observation, and sample size on power in studies of group differences in polynomial change","volume":"6","author":"Raudenbush","year":"2001","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib38","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102920","article-title":"Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review","volume":"78","author":"Subhani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes. Rev. Off. J. Int. Assoc. Study Obes."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib44","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/1740774505cn081oa","article-title":"Standardized mean differences in individually-randomized and cluster-randomized trials, with applications to meta-analysis","volume":"2","author":"White","year":"2005","journal-title":"Clin. Trials Lond. Engl."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112840_bib47","series-title":"Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib48","series-title":"Global status report on alcohol and health and treatment of substance use disorders","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.drugalcdep.2025.112840_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625002935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625002935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:32:03Z","timestamp":1767843123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625002935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"alternative-id":["S0376871625002935"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112840","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112840"}}